A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

BACKGROUND: A wide variety of human cancers exhibit dysregulated c-Met activity that has implications in oncogenesis. Phosphorylation of c-Met results in activation of the PI3K/AKT/mTOR pathway. Combined blockade of c-Met and mTOR pathways has shown efficacy in preclinical studies. Tivantinib is a c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Invest New Drugs
Auteurs principaux: Kyriakopoulos, Christos E., Braden, Amy M., Kolesar, Jill M., Eickhoff, Jens C., Bailey, Howard H., Heideman, Jennifer, Liu, Glenn, Wisinski, Kari B.
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5809175/
https://ncbi.nlm.nih.gov/pubmed/28004284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0418-8
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires